February 26, 2015—The Department of Health and Human Services Health Resources and Services Administration cannot second-guess Congress and rewrite the 340B orphan drug exclusion “to make the statute correspond with the agency’s policy preference,” brand-name drugmakers said yesterday in a court filing.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)